Thematic - 2026 Outlook - "5 More Years" (55pgs)

For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...

Morning Notes : ABI BB, AGS BB, GLPG NA, IBAB BB, UCB BB

: ABI BB, AGS BB, GLPG NA, IBAB BB, UCB BB

UCB Detailed results from Fintepla in CDD strengthen epilepsy franchis...

UCB presented detailed results of the positive phase 3 GEMZ study with Fintepla in CDKL5 deficiency disorder (CDD). The drug showed an estimated 52.7% median reduction in countable motor seizure frequency (CMSF) compared with placebo during a 14 week titration and maintenance period and a favourable safety profile. We view this as highly encouraging in this refractory epilepsy population. Given the infantile onset of CDD, we will be curious to see as of which age, patients could be included in t...

EVS Broadcast Equipment SA: 1 director

A director at EVS Broadcast Equipment SA sold 9,750 shares at 35.120EUR and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 12/05/2025

UCB : Upgrade de la guidance 2025 dans l’attente de plus d’éléments co...

UCB : 2025 guidance upgrade pending more details on profitability tren...

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 05/12/2025

Benelux Morning Notes

Ahold Delhaize: Peer Kroger 3Q25 results Kinepolis: Warner and Netflix enter exclusive deal negotiations UCB: FY25 guidance raised on Bimzelx's exceptional performance

Morning Notes : UCB BB

: UCB BB

UCB Announces another FY25 guidance upgrade

UCB announced an additional upgrade to its FY25 financial guidance, where it now expects revenue to exceed € 7.6b, representing +24% y/y (previously at least € 7b), and adj. EBITDA margin to be higher than 31% (previously at least 30%). This is the company's second guidance upgrade this year and shows that UCB's commercial momentum continues its upward trajectory supported by its 5 key growth drivers, including lead product Bimzelx which saw strong momentum in HS, as well as a favourable payer m...

Dynamic Top Pick List How to start 2026?

How to start 2026? We have selected for the KBC Securities Dynamic Top Pick List 12 large-cap companies — AB InBev, Aedifica, Argenx, ASMi, Azelis, DEME, D'Ieteren, Shurgard, Sofina, Vopak, WDP, and Wolters Kluwer — along with 3 small and mid-cap names (under €1.5bn in market capitalization): Corbion, EVS, and IBA. So, going into 2026, we maintain a balanced approach in our Dynamic Top Pick List, featuring 8 cyclical and 6 defensive stocks, with a particular emphasis on value stocks that have b...

Local Champions Mid Cap Conference Book 11.12.2025

This conference book is your guide to our annual Local Champions Mid Cap Conference set to take place on Thursday, 11 December 2025 at our historic building at Grand Place in Brussels. This event offers the possibility to have one-on-one meetings and/or attend small group sessions with the top management and/or IR of the following companies: BARCO | BEKAERT | DECEUNINCK | DEME | EVS | IBA | JENSEN GROUP | MATERIALISE | ONTEX | PROXIMUS | RECTICEL | XFAB

Benelux Morning Notes

Colruyt: Only 5 stores left to divest in France. EVS: Lower end of the range becomes the base case, on longer lead times. Fagron: Two EMEA acquisitions and California license for FSS. Kinepolis: “Wicked” achieves solid box office. OCI: Divesting Rotterdam ammonia terminal for €290m. Prosus: 1HFY26 results – on track

Morning Notes : BESI NA, EVS BB, FAGR BB, IVA FP, MONT BB, SEQUA BB, O...

: BESI NA, EVS BB, FAGR BB, IVA FP, MONT BB, SEQUA BB, ONWD BB

EVS Broadcast Equipment Pointing toward the lower end of the range aft...

Without giving exact numbers, EVS indicated they delivered y/y growth in 3Q25 revenue, offsetting the impact of major events in 3Q24 and signalling recovery from the delays seen in 1H25. Strong order intake for 4Q25 supports confidence in full-year growth, allowing EVS to reaffirm its revenue guidance of € 195m–€ 210m. That said, company-specific factors for 2025 point toward the lower end of the range as some 2025 orders may slip into 2026, reflecting longer lead times between order intake and ...

Deceuninck NV: 2 directors

Two Directors at Deceuninck NV bought 8,550 shares at between 2.030EUR and 2.050EUR. The significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...

Benelux Morning Notes

AkzoNobel: Announces merger of equals with US coatings peer Axalta. EVS: 3Q25 preview. GBL: Sale of half of Umicore stake. IBA: Negative press on poor Proton Therapy results, controversy about Dutch PT centres

UCB SA: 1 director

A director at UCB SA bought 200 shares at 216.000EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...

Morning Notes : ABN NA, CRBN NA, ENX FP, GBLB BB, PROX BB, UCB BB

: ABN NA, CRBN NA, ENX FP, GBLB BB, PROX BB, UCB BB